@gmj-georgia.bsky.socialResearchers have developed COMPASS, a breakthrough AI model that predicts immunotherapy response across multiple cancer types using tumor gene expre… #Artificialintelligence #Cancertreatment #Immunotherapy #Oncology #Precisionmedicine #Artificialintelligence #Cancertreatment #Immunotherapy #Onc…
@nursingtimes.bsky.social
@bcc2026.bsky.socialSubmit your abstract to the Breast Cancer Congress 2027 and showcase your work alongside researchers, clinicians, and oncology professionals worldwide.
June 17–18, 2027 | Zurich, Switzerland
@eventcentral.bsky.social🩺 International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027)
📍 Osaka, Japan
📅 25 Mar 2027
🎟️ 749 USD
#Oncology #EventCentral #Conference #Osaka
@tamedoncol.bsky.socialManagement of #testicular #cancer still diverges from guidelines.
Adj treatment remains common in stage I disease despite surveillance-based recommendations, while repeat imaging in stage IIA is inconsistently used.
More details 👉️ buff.ly/3oeKQLu
#oncology #realworld
@onclive.bsky.social🎙️ On this episode of #BreastCancerBriefing, Sara Nunnery, MD, and @matthewkurianmd.bsky.social discuss the role of AI in breast #oncology. @stelizabethnky.bsky.social #bcsm
👀 Watch the episode on our site or listen on your favorite podcast platform: www.onclive.com/view/oncolog...
@jmirlatestresearch.bsky.socialNew in JMIR Cancer: AI Agents for Multimodal #Oncology Diagnosis: Toward Transparent and Traceable Clinical Decision Support
@onclive.bsky.socialBexobrutideg drove responses across treatment lines in CLL/SLL, including in a subgroup of patients with treatment-naive disease. Dive into the #SOHO2026 data here #leusm #oncology www.onclive.com/view/bexobru...
@onclive.bsky.social💥 @fda.gov has accepted an NDA for bezuclastinib for the treatment of patients with advanced systemic mastocytosis, supported by phase 2 trial data.
Full details ➡️: onclive.com/view/fda-acc...
@onclive.bsky.social📈Updated data from the phase 3 ECHO trial showed improved efficacy for acalabrutinib plus BR in frontline MCL, providing insight about treatment sequencing.
Full details ➡️: www.onclive.com/view/echo-sh...
@dralhilali.comWhen someone has cancer, we often worry about saying the wrong thing. You don't need perfect words. Sometimes listening is enough - and sometimes they don't want to talk about cancer at all.
They just want to be themselves.
@onclive.bsky.social‼️ The @fda.gov has granted breakthrough therapy designation to daraxonrasib plus gemcitabine and nab-paclitaxel for treatment-naive mPDAC. #pancsm #oncology
See our site for the full story ➡️: www.onclive.com/view/fda-gra...
@onclive.bsky.social🗣️ OSE2101 Plus Pembrolizumab as Maintenance Boosts PFS in Platinum-Sensitive Ovarian Cancer
Read more here ➡️: www.onclive.com/view/ose2101...
@bioinformatics.cnio.es@onclive.bsky.social📰 @ascocancer.bsky.social published its first living guideline on the treatment of recurrent high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer. @jco-asco.bsky.social #gyncsm #oncology
Learn more: www.onclive.com/view/asco-is...
@gih.geCancer care is changing.
Precision medicine, immunotherapy, AI and earlier detection are reshaping oncology.
Explore the future of cancer research: www.newsletter.co.uk/your-world/c...
@bifold.berlin"I am particularly excited that the funding will allow us to pilot our developed system in a real-world clinical setting," says Jamshidi Idaji.
@monalisarout1701.bsky.socialGastric cancer advances outlined:
🔬 7.7% cancer deaths worldwide
🔬 69% cases in Asia, high incidence in minorities
🔬 5-year survival varies, 36.4% overall
🔬 HER2 and PD-L1 testing in metastatic cases
#GastricCancer #Oncology #Immunotherapy https://tnyp.me/mkzMBbpw/s
@meducationai.bsky.socialHow much time would it actually take to keep up with oncology research? My honest estimate is in the first ten seconds, and it's more than you'd think.
Here's the AI agent we built to shrink it, free for anyone treating cancer.
@hemehub.bsky.social🌟🔎Today’s questions!
Swipe to see the answers and explanations!
#SMM #SmolderingMultipleMyeloma #MultipleMyeloma #Hematology #HemeOnc #Oncology #Immunology #MedicalEducation #MedEd #ClinicalHematology #HemeHub
